- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06593470
Prevenção do uso de substâncias baseadas em atenção plena (Minds-up) (MINDS-UP)
Prevenção do uso de substâncias baseadas em atenção plena (Minds-up): um estudo controlado randomizado
The goal of this clinical trial is to test the feasibility, behavioral/neural mechanisms, and preliminary efficacy of "MINDfulness-based Substance Use Prevention Program," or "MINDS-UP", a novel substance use prevention meditation intervention for children and adolescents between the ages of 10 and 14. The aims of the study are:
Aim 1: Determine feasibility and acceptability of MINDS-UP as a preventive intervention via a) retention, b) attendance, c) teacher-rated participation, d) student-rated participation, e) homework completion, and f) acceptability.
Aim 2: Evaluate neuropsychological mechanisms (target engagement) of MINDS-UP.
Aim 3 (Exploratory): Assess preliminary efficacy of MINDS-UP on substance use initiation (SUI).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: David C Saunders, MD, PhD
- Número de telefone: 914-409-6807
- E-mail: david.saunders@nyspi.columbia.edu
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Youth is ages 10-14 years on the day of screening [i.e., does not turn 15 before or on the day of screening]
- Youth has access to a smartphone, tablet, or computer with Wi-Fi
- Youth and parent are English-speaking
Exclusion Criteria:
1. The youth has been diagnosed with or received treatment for one of the following mental health problems: depression, bipolar disorder, schizophrenia, autism spectrum disorder, intellectual disability, or substance use disorder.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Sport: Prevention Plus Wellness (PPW)
Sport: Prevention Plus Wellness (PPW) is a brief, evidence-based substance use prevention program for youth. PPW consists of a single self-administered 45-minute session that is interactive and intended for use by youth in the home setting. It involves screening youth to increase awareness of their current health behaviors; motivational enhancement for change; and establishing a behavior goal plan. |
PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45 minute self-administered online course.
Outros nomes:
|
|
Experimental: PPW + MINDS-UP
MINDS-UP consists of 4 x 60-minute sessions, once weekly over 4 weeks. MINDS-UP will be delivered to participants remotely, in a 1:1 setting, taught by the meditation teachers that will be hired and trained by Dr. Saunders. Additionally, participants will be provided audio files of 5-10-minute guided meditation practices, led by Dr. Saunders, as homework. Participants randomized to MINDS-UP will also complete PPW, a 45 minute, self-administered course. |
PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45 minute self-administered online course.
Outros nomes:
MINDS-UP is a substance use prevention program for children/adolescents.It consists of 4 x 60-minute sessions, once weekly over 4 weeks. The four MINDS-UP classes will focus on the following: Mindfulness of Body; Mindfulness of Mind; Mindfulness of Environment/Community; Kindness, Compassion, Joy and Equanimity, respectively. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Retention
Prazo: Completion of Study (up to 36 months)
|
Percent of participants who completed all study procedures among those who were randomized |
Completion of Study (up to 36 months)
|
|
Attendance
Prazo: Completion of Study (up to 36 months)
|
Percent of scheduled sessions that were completed by the participant. |
Completion of Study (up to 36 months)
|
|
Teacher Rated Participation
Prazo: Completion of Study (up to 36 months)
|
Research Assessment Package for Schools - Teacher Rated |
Completion of Study (up to 36 months)
|
|
Student-Rated Participation
Prazo: Completion of Study (up to 36 months)
|
Research Assessment Package for Schools - Student Engagement |
Completion of Study (up to 36 months)
|
|
Homework Completion
Prazo: Completion of Study (up to 36 months)
|
Percentage of assigned homeworks that were completed by the participant. |
Completion of Study (up to 36 months)
|
|
Acceptability
Prazo: Completion of Study (up to 36 months)
|
Acceptability of Intervention Measure |
Completion of Study (up to 36 months)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Problems (parent-report)
Prazo: 4-8 weeks, 6 months, and 12 months
|
Pre-assessment to post-assessment (and 6- and 12-month follow-up) difference in the total score on the total problems subscale on the Child Behavior Checklist (CBCL), which is comprised of 98 questions; individual item scores range from 0 to 2; higher scores indicate higher amount of behavioral problems |
4-8 weeks, 6 months, and 12 months
|
|
ADHD Symptoms
Prazo: 4-6 weeks, 6 months, and 12 months
|
Pre-assessment to post-assessment (and 6- and 12-month follow-up) difference in score on the ADHD Rating Scale, an 18-item parent-report assessment that measures adolescent behaviors related to ADHD (inattentiveness, hyperactivity). |
4-6 weeks, 6 months, and 12 months
|
|
Suicidal Thoughts/Behaviors
Prazo: 4-6 weeks, 6 months, 12 months
|
The C-SSRS is a gold-standard assessment tool for suicide risk. This tool will be administered at every visit. |
4-6 weeks, 6 months, 12 months
|
|
Alcohol sipping
Prazo: 4-6 weeks, 6 months, and 12 months
|
Low-level and early alcohol use as characterized by the iSay Sipping Inventory. This survey characterizes low level and first/early alcohol use, including age at first sip, whether that drink was completed, and behaviors after the first sip. |
4-6 weeks, 6 months, and 12 months
|
|
Tobacco Use
Prazo: 4-6 weeks, 6 months, and 12 months
|
Tobacco use as measured by Tobacco Low Level Use Measure. This is a short tool that measures number of times used, type of tobacco/nicotine used, duration of use, and frequency of use. |
4-6 weeks, 6 months, and 12 months
|
|
Cannabis Use
Prazo: 4-6 weeks, 6 months, and 12 months
|
Cannabis use as measured by the Marijuana Low-Level Use Measure, a short tool that measures early/first use of cannabis. |
4-6 weeks, 6 months, and 12 months
|
|
Total Problems (adolescent report)
Prazo: 4-6 weeks, 6 months, 12 months
|
The Youth Self Report (YSR) is the self-report adolescent version of the Child Behavior Checklist, and is used to assess emotional and behavioral problems in children and adolescents. |
4-6 weeks, 6 months, 12 months
|
|
Mindfulness
Prazo: 4-6 weeks, 6 months, and 12 months
|
Pre-assessment to post-assessment (and 6- and 12-month follow-up) difference in score on the Child and Adolescent Mindfulness Measure (CAMM); the CAMM is a 10-item measure of self-reported mindfulness; scores range from 0 to 40, with higher scores indicating higher mindfulness |
4-6 weeks, 6 months, and 12 months
|
|
Anxiety and Depression
Prazo: 4-6 weeks, 6 months, and 12 months
|
Pre-assessment to post-assessment (and 6 and 12 month-follow-up) difference in score on the Revised Childhood Anxiety and Depression scale, a 47-item self-report scale that assesses childhood/adolescent anxiety and depression symptoms across six sub-domains. |
4-6 weeks, 6 months, and 12 months
|
|
Perceived Tolerance of Use
Prazo: baseline
|
The Perceived Tolerance of Use is a tool that assesses peer tolerance of use of substance use (of substances that a participant has heard of, meaning the number of items is variable). It is a tool that is used in the ABCD study and the Monitoring the Future Study, the two most comprehensive studies of adolescent substance use. |
baseline
|
|
Perceived Harm of Substance Use
Prazo: baseline
|
The Perceived Harm of Substance Use tool assesses perceived harm of substance use (of substances that a participant has heard of, meaning the number of items is variable). It is used in the ABCD study and the Monitoring the Future Study, the two most comprehensive studies of adolescent substance use. |
baseline
|
|
Beliefs About Alcohol Effects
Prazo: baseline
|
The Brief Comprehensive Effects of Alcohol Questionnaire is a 15-item self-report version of the Comprehensive Effects of Alcohol Questionnaire that is used by the ABCD study to assess an adolescent's expectations of using alcohol. |
baseline
|
|
Beliefs About Smoking Effects
Prazo: baseline
|
The Adolescent Smoking Consequences Questionnaire (ASCQ) is a 30-item self-report instrument used to assess outcome expectancies of cigarette smoking among adolescents. |
baseline
|
|
Beliefs About Cannabis Effects
Prazo: baseline
|
Brief -Marijuana Effect Expectancies Questionnaire (MEEQ-B) is a 6-item self-report assessment of an adolescent's expected effect of marijuana. |
baseline
|
|
Risk and Protective Factors
Prazo: Baseline
|
The Community Risk and Protective Factors Survey is a 24-item parent-report tool to assess adolescent's experience of exposure to substance use risk and protective factors in the community. |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- #Pro00076319
- K12DA000357 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .